Iron deficiency in chronic kidney disease and the new generation of intravenous iron

Abstract

Anemia is the most common complication of chronic kidney disease (CKD) and the main cause of poor prognosis in CKD patients. Iron deficiency (ID) is the second most important factor in the occurrence of anemia in CKD besides EPO deficiency, and iron is currently the main treatment for iron deficiency in patients with CKD anemia. Iron supplements are divided into intravenous iron and oral iron supplements. Oral iron is often ineffective due to its gastrointestinal side effects and low absorption efficiency. Traditional intravenous iron can only be administered in small single doses due to safety restrictions. New intravenous iron agents have emerged. This article provides a brief overview of current iron metabolism in chronic kidney disease, causes of iron deficiency, iron status and new intravenous iron agents available.